Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | P4HB | P07237 | 3/20 | 0.71 |
| ▸ | TP53 | P04637 | 2/20 | 0.71 |
| ▸ | USP2 | O75604 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | THRB | P10828 | 1/20 | 0.71 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.66 |
| ▸ | BRAF | P15056 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16501078 | 0.84 | MDM2 (0.79) | MAPTP4HBMDM2BRAFKDM4E | |
| SCHEMBL13836628 | 0.83 | P4HB (1.00) | MAPTP4HBTP53USP2LMNA | |
| SCHEMBL9965599 | 0.83 | MDM2 (0.67) | MAPTP4HBTP53MDM2BRAF | |
| SCHEMBL15783181 | 0.82 | P4HB (0.73) | MAPTP4HBTP53USP2LMNA | |
| SCHEMBL21842384 | 0.81 | P4HB (0.72) | MAPTP4HBTP53USP2LMNA | |
| SCHEMBL7994574 | 0.81 | MDM2 (0.69) | MAPTLMNAMDM2KDM4EALDH1A1 | |
| SCHEMBL16501068 | 0.81 | MAPT (0.61) | MAPTP4HBTP53LMNAMDM2 | |
| SCHEMBL16501067 | 0.80 | MDM2 (0.76) | MAPTP4HBMDM2BRAFKDM4E | |
| SCHEMBL9962880 | 0.80 | MDM2 (0.76) | MAPTP4HBTP53MDM2BRAF | |
| SCHEMBL7980153 | 0.80 | MDM2 (1.00) | MAPTP4HBLMNAMDM2BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190256471-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE AR (US) | 2019-08-22 | — | — | US | disclosed |
| US-10301265-B2 | Small molecule inhibitors of botulinum neurotoxins | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2019-05-28 | — | — | US | disclosed |
| US-9273031-B2 | Combination therapy with MDM2 and EFGR inhibitors | Errico, Joseph P. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273031-B2 | Combination therapy with MDM2 and EFGR inhibitors | Errico, Joseph P. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9238641-B2 | — | — | 2016-01-19 | — | — | US | disclosed |
| US-9238641-B2 | — | — | 2016-01-19 | — | — | US | disclosed |
| US-9073858-B2 | Methods of targeted drug development | Errico, Joseph P. (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073858-B2 | Methods of targeted drug development | Errico, Joseph P. (US) | 2015-07-07 | — | — | US | disclosed |
| US-9023354-B2 | Combination therapy with MDM2 and EFGR inhibitors | Errico, Joseph P. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9023354-B2 | Combination therapy with MDM2 and EFGR inhibitors | Errico, Joseph P. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20120196853-A1 | Novel Quinoline-Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-02 | — | — | US | disclosed |
| US-20120196853-A1 | Novel Quinoline-Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-02 | — | — | US | disclosed |
| US-20120156197-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | Errico, Joseph P. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120156197-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | Errico, Joseph P. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012012653-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | ERRICO JOSEPH P (US) | 2012-01-26 | — | — | WO | disclosed |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110294848-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2011-12-01 | — | — | US | disclosed |
| US-20110294848-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2011-12-01 | — | — | US | disclosed |
| WO-2009151972-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | , THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, ON BEHALF OF U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156197-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | TP53, EGFR, MDM2 | MAPT 3015/4885P4HB 4025/4885TP53 1/4885 |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | MAPT 1076/4885P4HB 2320/4885TP53 230/4885 |
| US-20120196853-A1 | Novel Quinoline-Hepcidine Antagonists | HAMP, SLC40A1, FTH1 | MAPT 4808/4885P4HB 1974/4885TP53 4470/4885 |
| US-10301265-B2 | Small molecule inhibitors of botulinum neurotoxins | RAC2, BTN3A1, GDI1 | MAPT 2064/4885P4HB 2999/4885TP53 3978/4885 |
| US-20190256471-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | RAC2, BTN3A1, GDI1 | MAPT 2064/4885P4HB 2999/4885TP53 3978/4885 |
| US-20110294848-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | RAC2, BTN3A1, GDI1 | MAPT 2064/4885P4HB 2999/4885TP53 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.